Vertex Pharmaceuticals Inc (VRTX)vsZevra Therapeutics Inc. (ZVRA)
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
ZVRA
Zevra Therapeutics Inc.
$9.13
-0.22%
HEALTHCARE · Cap: $537.21M
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 11172% more annual revenue ($12.00B vs $106.47M). ZVRA leads profitability with a 78.2% profit margin vs 32.9%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).
VRTX
Strong Buy66
out of 100
Grade: B-
ZVRA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Margin of Safety
+7.6%
Fair Value
$9.18
Current Price
$9.13
$0.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Every $100 of equity generates 86 in profit
Keeps 78 of every $100 in revenue as profit
Strong operational efficiency at 27.3%
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
1.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 78.2% and operating margin at 27.3%.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : ZVRA
The primary concerns for ZVRA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
VRTX profiles as a mature stock while ZVRA is a value play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.94 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 62/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?